A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer’s Disease

Herrmann, Nathan; Lanctôt, Krista L.; Rothenburg, Lana S.; Eryavec, Goran
January 2007
Dementia & Geriatric Cognitive Disorders;2007, Vol. 23 Issue 2, p116
Academic Journal
Background/Aims: To assess the efficacy and tolerability of valproate for the treatment of agitation and aggression in moderate-to-severe Alzheimer’s disease (AD). Methods: This was a randomized, double-blind, placebo-controlled crossover trial of valproate in institutionalized AD patients. Patients were assessed with the Neuropsychiatric Inventory (NPI) and Cohen-Mansfield Agitation Inventory at baseline and after 6 weeks of treatment with valproate and placebo, with 2 weeks between phases to allow for placebo washout and tapering. Results: Fourteen patients (8 male/6 female) aged 85.6 ± 4.5 years with baseline Mini Mental State Examination scores of 4.5 ± 4.6 and NPI agitation/aggression scores of 6.4 ± 3.5 were randomized to treatment. NPI agitation/aggression treatment change scores significantly worsened during valproate treatment compared with placebo (Z = –2.03, p = 0.04). Tolerability of valproate was also poor, with patients experiencing a significantly greater mean number of adverse events during valproate therapy compared to placebo (Z = –2.82, p = 0.005). Conclusion: Valproate is not effective for the management of agitation in moderate-to-severe AD, and may be poorly tolerated in this population. Copyright © 2007 S. Karger AG, Basel


Related Articles

  • When Someone You Love Has ALZHEIMER'S DISEASE. Mueller, Michelle // Current Health 2;Dec2003, Vol. 30 Issue 4, p29 

    Focuses on Alzheimer's disease, a disorder that causes the gradual loss of brain cells. INSET: In Her Own Words.

  • Cortical Change in Alzheimer's Disease Detected with a Disease-specific Population-based Brain Atlas. Thompson, Paul M.; Woods, Roger P.; Zoumalan, Chris I.; Lindshield, Chris J.; Blanton, Rebecca E.; Moussai, Jacob; Holmes, Colin J.; Toga, Arthur W.; Mega, Michael S.; Cummings, Jeffrey L. // Cerebral Cortex;Jan2001, Vol. 11 Issue 1, p1 

    Presents information on a study on Alzheimer's disease (AD). Details on the population-based maps of cortical gray matter loss in AD; Use of computational strategy to compute gyral patterns; Hypothesis; Materials and methods; Results; Discussion.

  • Alzheimer's Disease: When Free Radicals Run Amok. Butterfield, Allan // Drug Discovery & Development;Jan2003, Vol. 6 Issue 1, p12 

    Focuses on the molecular basis of the disorder Alzheimer's disease. Pathogenesis of Alzheimer's disease; Definition of potentially additional therapeutic targets.

  • A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimer's Disease. Cole, G.M.; Yang, F.; Lim, G.P.; Cummings, J.L.; Masterman, D.L.; Frautschy, S.A. // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Mar2003, Vol. 3 Issue 1, p15 

    Alzheimer's disease (AD) is believed to involve increased soluble but toxic beta amyloid (A�) peptide aggregates, leading to the accumulation of insoluble A� deposits, inflammation, oxidative damage, tau pathology and ultimately cognitive deficits. Blocking A� formation early...

  • Preface. Emmerling, Mark R.; Roher, Alex E. // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Mar2003, Vol. 3 Issue 1, p1 

    Introduces articles on the future prospects for the prevention of Alzheimer's disease, published in the March 2003 issue of 'Current Medicinal Chemistry.'

  • Alzheimer Disease: Clinical and Biological Heterogeneity. Friedland, Robert P.; koss, Elizabeth; Haxby, James V.; Grady, Cheryl L.; Luxenburg, Jay; Schapiro, Mark B.; Kaye, Jeffrey // Annals of Internal Medicine;8/15/88, Vol. 109 Issue 4, p298 

    Focuses on the clinical and biological heterogeneity of Alzheimer's disease. Variability of clinical manifestations of the disease; Changes in noncognitive behaviors of patients with the disease; Heterogenous patterns of regional cerebral glucose use; Longitudinal changes in brain metabolism.

  • Neuroglobin could protect against Alzheimer's.  // Medical Device Daily;8/9/2010, Vol. 14 Issue 153, Special section p1 

    The article discusses a research study which described how neuroglobin can act as protection against Alzheimer's disease.

  • Alzheimer's passes diabetes as sixth leading case of death in U.S.  // Edgewood Enterprise (TX);9/18/2008, Vol. 101 Issue 38, p6 

    The article reports on the new findings of the National Center for Health Statistics that Alzheimer's disease is now the sixth leading cause of death in the U.S.

  • Alzheimer's Update: The Immune System Connection. Craig, Christine // Alive: Canada's Natural Health & Wellness Magazine;Jan2003, Issue 243, p52 

    Presents update on research about Alzheimer's disease. Possible involvement of inflammation and overactive immune function in the pathogenesis of the disease; Role of inflammatory immune factor interleukin-1 and interleukin-6 in the destruction of neurons in the brain.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics